TGF-β Pathway as a Therapeutic Target in Bone Metastases

Author(s): Patricia Juarez, Theresa A. Guise

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 11 , 2010

Become EABM
Become Reviewer


Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.

Keywords: TGF-β, TGF-β receptors, bone, metastases, TGF-β inhibitors, bone metastases, breast cancer, prostatic cancer, melanoma

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [1301 - 1312]
Pages: 12
DOI: 10.2174/138161210791034049
Price: $65

Article Metrics

PDF: 20